beta-alanine has been researched along with Brain Hemorrhage in 33 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compared with warfarin, dabigatran is associated with less intracranial hemorrhage, but an increased risk of myocardial infarction." | 9.17 | Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? ( Connolly, SJ; Coppens, M; Dale, B; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Paikin, JS; Weitz, JI; Whitlock, RP; Young, E, 2013) |
| "Analysis of 18 113 participants with atrial fibrillation in the Randomized Evaluation of Long-term anticoagulant therapY (RE-LY) trial assigned to adjusted-dose warfarin (target international normalized ratio, 2-3) or dabigatran (150 mg or 110 mg, both twice daily)." | 9.16 | Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. ( Connolly, SJ; Diener, HC; Ezekowitz, MD; Hart, RG; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S, 2012) |
| "We formed new-user cohorts of propensity score-matched elderly patients enrolled in Medicare who initiated dabigatran or warfarin for treatment of nonvalvular atrial fibrillation between October 2010 and December 2012." | 7.81 | Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. ( Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R, 2015) |
| " We investigated the risks of ischemic stroke and intracranial hemorrhage (ICH) in relation to warfarin at various TTRs in a real-world cohort of Chinese patients with atrial fibrillation receiving warfarin and compared with those on dabigatran, aspirin, and no therapy." | 7.81 | Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. ( Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Lau, CP; Lau, KK; Leung, GK; Lip, GY; Siu, CW; Tse, HF; Yeung, CY, 2015) |
| "In randomized trials, patients with atrial fibrillation (AF) receiving dabigatran, a direct oral anticoagulant, had lower risk of intracranial bleeding (ICB) than those on warfarin." | 7.80 | Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. ( Alonso, A; Bengtson, LG; Chen, LY; Lakshminarayan, K; Lutsey, PL; MacLehose, RF, 2014) |
| "Compared with patients who never used dabigatran, patients who used dabigatran at least once were younger, were more likely to be white, had lower international normalized ratio time in therapeutic range on warfarin, had lower stroke risk scores, and had similar bleeding risk scores." | 7.80 | Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. ( Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS, 2014) |
| "There is a remarkable lack of consensus among vascular neurologists regarding the assessment and treatment of acute stroke patients on dabigatran." | 7.79 | Treatment of acute stroke in patients on dabigatran: a survey of US stroke specialists. ( Cucchiara, B; Kasner, SE; Messe, S; Mullen, MT; Rybinnik, I, 2013) |
| "The concept of net clinical benefit has been used to quantify the balance between risk of ischaemic stroke (IS) and risk of intracranial haemorrhage (ICH) with the use oral anticoagulant therapy (OAC) in the setting of non-valvular atrial fibrillation (AF), and has shown that patients at highest risk of stroke and thromboembolism gain the greatest benefit from OAC with warfarin." | 7.78 | Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. ( Banerjee, A; Lane, DA; Lip, GY; Torp-Pedersen, C, 2012) |
| "In patients aged 65 years or older with nonvalvular AF at increased risk for stroke (CHADS₂ score ≥1 or equivalent), dabigatran may be a cost-effective alternative to warfarin depending on pricing in the United States." | 7.77 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. ( Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP, 2011) |
| "NOACs have shown a large reduction in intracranial hemorrhage compared with warfarin." | 6.49 | [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran]. ( Bosnyák, E; Csécsei, P; Deli, G; Fehér, G; Szapary, L, 2013) |
| "Compared with warfarin, dabigatran is associated with less intracranial hemorrhage, but an increased risk of myocardial infarction." | 5.17 | Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? ( Connolly, SJ; Coppens, M; Dale, B; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Paikin, JS; Weitz, JI; Whitlock, RP; Young, E, 2013) |
| "Analysis of 18 113 participants with atrial fibrillation in the Randomized Evaluation of Long-term anticoagulant therapY (RE-LY) trial assigned to adjusted-dose warfarin (target international normalized ratio, 2-3) or dabigatran (150 mg or 110 mg, both twice daily)." | 5.16 | Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. ( Connolly, SJ; Diener, HC; Ezekowitz, MD; Hart, RG; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S, 2012) |
| "Dabigatran is a direct thrombin inhibitor gaining popularity as a stroke prevention agent in patients with atrial fibrillation." | 4.89 | Traumatic intracranial hemorrhage in patients taking dabigatran: report of 3 cases and review of the literature. ( Abel, TJ; Greenlee, JD; Grossbach, A; Howard, MA; Jackson, AW; Viljoen, SV; Wassef, SN, 2013) |
| "In patients with atrial fibrillation (AF) oral anticoagulation with vitamin-K antagonists (warfarin, phenprocoumon) is effective both for primary and secondary stroke prevention yielding a 60-70% relative reduction in stroke risk compared with placebo, as well as a mortality reduction of 26 percent." | 4.89 | Novel oral anticoagulants in secondary prevention of stroke. ( Diener, HC; Easton, JD; Hankey, GJ; Hart, RG, 2013) |
| "We formed new-user cohorts of propensity score-matched elderly patients enrolled in Medicare who initiated dabigatran or warfarin for treatment of nonvalvular atrial fibrillation between October 2010 and December 2012." | 3.81 | Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. ( Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R, 2015) |
| " We investigated the risks of ischemic stroke and intracranial hemorrhage (ICH) in relation to warfarin at various TTRs in a real-world cohort of Chinese patients with atrial fibrillation receiving warfarin and compared with those on dabigatran, aspirin, and no therapy." | 3.81 | Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. ( Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Lau, CP; Lau, KK; Leung, GK; Lip, GY; Siu, CW; Tse, HF; Yeung, CY, 2015) |
| "The clinical data and treatment summaries of 9 intracranial bleeds that developed during dabigatran treatment in 8 patients with non-valvular atrial fibrillation were retrospectively reviewed." | 3.80 | Intracranial hemorrhage during dabigatran treatment. ( Ago, T; Fujimoto, S; Kameda, K; Kitazono, T; Kokuba, K; Komori, M; Matsuoka, H; Nagata, S; Okada, Y; Shono, T; Yasaka, M; Yoshida, M, 2014) |
| "In randomized trials, patients with atrial fibrillation (AF) receiving dabigatran, a direct oral anticoagulant, had lower risk of intracranial bleeding (ICB) than those on warfarin." | 3.80 | Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. ( Alonso, A; Bengtson, LG; Chen, LY; Lakshminarayan, K; Lutsey, PL; MacLehose, RF, 2014) |
| "Compared with patients who never used dabigatran, patients who used dabigatran at least once were younger, were more likely to be white, had lower international normalized ratio time in therapeutic range on warfarin, had lower stroke risk scores, and had similar bleeding risk scores." | 3.80 | Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. ( Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS, 2014) |
| "There is a remarkable lack of consensus among vascular neurologists regarding the assessment and treatment of acute stroke patients on dabigatran." | 3.79 | Treatment of acute stroke in patients on dabigatran: a survey of US stroke specialists. ( Cucchiara, B; Kasner, SE; Messe, S; Mullen, MT; Rybinnik, I, 2013) |
| "The concept of net clinical benefit has been used to quantify the balance between risk of ischaemic stroke (IS) and risk of intracranial haemorrhage (ICH) with the use oral anticoagulant therapy (OAC) in the setting of non-valvular atrial fibrillation (AF), and has shown that patients at highest risk of stroke and thromboembolism gain the greatest benefit from OAC with warfarin." | 3.78 | Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. ( Banerjee, A; Lane, DA; Lip, GY; Torp-Pedersen, C, 2012) |
| "In patients aged 65 years or older with nonvalvular AF at increased risk for stroke (CHADS₂ score ≥1 or equivalent), dabigatran may be a cost-effective alternative to warfarin depending on pricing in the United States." | 3.77 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. ( Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP, 2011) |
| "NOACs have shown a large reduction in intracranial hemorrhage compared with warfarin." | 2.49 | [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran]. ( Bosnyák, E; Csécsei, P; Deli, G; Fehér, G; Szapary, L, 2013) |
| "dabigatran (Pradaxa®) is a direct and specific thrombin inhibitor." | 2.49 | [General characteristics of the new oral anticoagulants]. ( Berrut, G; Chevalet, P; De Decker, L; Gegu, M; Piloquet, FX, 2013) |
| "Seven were admitted for an intracranial hemorrhage (ICH) and four for a gastrointestinal hemorrhage (GIH)." | 1.40 | Clinical experience of life-threatening dabigatran-related bleeding at a large, tertiary care, academic medical center: a case series. ( Ditch, K; Miller, MA; Ross, B; Tran, M, 2014) |
| "Dabigatran is a newly available oral direct thrombin inhibitor approved for anticoagulation therapy to prevent strokes in patients with nonvalvular atrial fibrillation." | 1.39 | Removal of dabigatran by hemodialysis. ( Chang, DN; Chin, AI; Dager, WE, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 33 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Southworth, MR | 2 |
| Reichman, ME | 2 |
| Unger, EF | 1 |
| Aron, JL | 1 |
| Gosselin, R | 1 |
| Moll, S | 1 |
| Arkin, CF | 1 |
| Mantha, S | 1 |
| Awad, AJ | 1 |
| Walcott, BP | 1 |
| Stapleton, CJ | 1 |
| Yanamadala, V | 1 |
| Nahed, BV | 1 |
| Coumans, JV | 1 |
| Wassef, SN | 1 |
| Abel, TJ | 1 |
| Grossbach, A | 1 |
| Viljoen, SV | 1 |
| Jackson, AW | 1 |
| Howard, MA | 1 |
| Greenlee, JD | 1 |
| Szapary, L | 1 |
| Fehér, G | 1 |
| Bosnyák, E | 1 |
| Deli, G | 1 |
| Csécsei, P | 1 |
| Potpara, TS | 1 |
| Lip, GY | 3 |
| Bennaghmouch, N | 1 |
| Ten Berg, JM | 1 |
| Diener, HC | 2 |
| Easton, JD | 1 |
| Hankey, GJ | 1 |
| Hart, RG | 4 |
| Schulman, S | 1 |
| Kono, S | 1 |
| Deguchi, K | 1 |
| Omote, Y | 1 |
| Yunoki, T | 1 |
| Yamashita, T | 1 |
| Kurata, T | 1 |
| Ikeda, Y | 1 |
| Abe, K | 1 |
| Ross, B | 1 |
| Miller, MA | 1 |
| Ditch, K | 1 |
| Tran, M | 1 |
| Gegu, M | 1 |
| Chevalet, P | 1 |
| Piloquet, FX | 1 |
| Berrut, G | 1 |
| De Decker, L | 1 |
| Komori, M | 1 |
| Yasaka, M | 1 |
| Kokuba, K | 1 |
| Matsuoka, H | 1 |
| Fujimoto, S | 1 |
| Yoshida, M | 1 |
| Kameda, K | 1 |
| Shono, T | 1 |
| Nagata, S | 1 |
| Ago, T | 1 |
| Kitazono, T | 1 |
| Okada, Y | 1 |
| Hirano, T | 1 |
| Alonso, A | 1 |
| Bengtson, LG | 1 |
| MacLehose, RF | 1 |
| Lutsey, PL | 1 |
| Chen, LY | 1 |
| Lakshminarayan, K | 1 |
| Vaughan Sarrazin, MS | 1 |
| Jones, M | 1 |
| Mazur, A | 1 |
| Chrischilles, E | 1 |
| Cram, P | 1 |
| Graham, DJ | 1 |
| Wernecke, M | 1 |
| Zhang, R | 1 |
| Levenson, M | 1 |
| Sheu, TC | 1 |
| Mott, K | 1 |
| Goulding, MR | 1 |
| Houstoun, M | 1 |
| MaCurdy, TE | 1 |
| Worrall, C | 1 |
| Kelman, JA | 1 |
| Eikelboom, JW | 3 |
| Ho, CW | 1 |
| Ho, MH | 1 |
| Chan, PH | 2 |
| Hai, JJ | 2 |
| Cheung, E | 1 |
| Yeung, CY | 1 |
| Lau, KK | 1 |
| Chan, KH | 1 |
| Lau, CP | 1 |
| Leung, GK | 1 |
| Tse, HF | 1 |
| Siu, CW | 2 |
| Feng, X | 1 |
| Huan, Y | 1 |
| Lv, Y | 1 |
| Siddon, AJ | 1 |
| Rinder, HM | 1 |
| Hendrickson, JE | 1 |
| Tormey, CA | 1 |
| Freeman, JV | 1 |
| Zhu, RP | 1 |
| Owens, DK | 1 |
| Garber, AM | 1 |
| Hutton, DW | 1 |
| Go, AS | 1 |
| Wang, PJ | 1 |
| Turakhia, MP | 1 |
| del Zoppo, GJ | 1 |
| Eliasziw, M | 1 |
| Banerjee, A | 1 |
| Lane, DA | 1 |
| Torp-Pedersen, C | 1 |
| Parry, PV | 1 |
| Engh, JA | 1 |
| Quinlan, DJ | 1 |
| Connolly, SJ | 3 |
| Yusuf, S | 2 |
| Yang, S | 1 |
| Wallentin, L | 1 |
| Reilly, PA | 1 |
| Ezekowitz, MD | 1 |
| Freeman, WD | 1 |
| Kuo, R | 1 |
| Aguilar, MI | 1 |
| Stöllberger, C | 1 |
| Finsterer, J | 1 |
| Chang, DN | 1 |
| Dager, WE | 1 |
| Chin, AI | 1 |
| Dale, B | 1 |
| Weitz, JI | 1 |
| Young, E | 1 |
| Paikin, JS | 1 |
| Coppens, M | 1 |
| Whitlock, RP | 1 |
| Ginsberg, JS | 1 |
| Hirsh, J | 1 |
| Rybinnik, I | 1 |
| Mullen, MT | 1 |
| Messe, S | 1 |
| Kasner, SE | 1 |
| Cucchiara, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Monitor System for the Safety of Dabigatran Anticoagulation Treatment in Nonvalvular Atrial Fibrillation[NCT02414035] | 1,496 participants (Actual) | Observational | 2015-03-22 | Completed | |||
| Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation[NCT04357288] | 1,200 participants (Anticipated) | Interventional | 2020-12-16 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for beta-alanine and Brain Hemorrhage
| Article | Year |
|---|---|
Dabigatran, intracranial hemorrhage, and the neurosurgeon.
Topics: Aged, 80 and over; Animals; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; | 2013 |
Traumatic intracranial hemorrhage in patients taking dabigatran: report of 3 cases and review of the literature.
Topics: Accidental Falls; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Craniocere | 2013 |
[Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2013 |
Novel oral anticoagulants in non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini | 2013 |
New oral anticoagulants after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; C | 2013 |
Novel oral anticoagulants in secondary prevention of stroke.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabig | 2013 |
Advantages and limitations of the new anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; D | 2014 |
[General characteristics of the new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabig | 2013 |
2 trials available for beta-alanine and Brain Hemorrhage
| Article | Year |
|---|---|
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; | 2012 |
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intracrania | 2013 |
23 other studies available for beta-alanine and Brain Hemorrhage
| Article | Year |
|---|---|
Dabigatran and postmarketing reports of bleeding.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Gastrointestinal Hemorrhage | 2013 |
Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor VIIa; Humans; Intracranial Hem | 2014 |
Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Disease Models, An | 2014 |
Clinical experience of life-threatening dabigatran-related bleeding at a large, tertiary care, academic medical center: a case series.
Topics: Academic Medical Centers; Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Comb | 2014 |
Intracranial hemorrhage during dabigatran treatment.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2014 |
New era of oral anticoagulation for Japanese non-valvular atrial fibrillation patients.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intrac | 2014 |
Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr | 2014 |
Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2014 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles | 2015 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles | 2015 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles | 2015 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles | 2015 |
Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Huma | 2015 |
Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2015 |
Letter by Feng et al regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracra | 2015 |
Response to letter regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracra | 2015 |
Is thrombin time too sensitive to dabigatran anticoagulation for clinical decision making in the setting of acute hemorrhage?
Topics: Acute Disease; Aged; Benzimidazoles; beta-Alanine; Dabigatran; Decision Making; Fibrinolytic Agents; | 2015 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Ben | 2011 |
New options in anticoagulation for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intention to | 2011 |
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Cohort | 2012 |
Application of the RELY study to lifetime risks of atrial fibrillation: implications for spontaneous intracranial hemorrhage.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intracranial H | 2012 |
Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Ev | 2012 |
Letter by Freeman et al regarding article, "Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY Trial".
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracranial Hemorrhages; Male; W | 2012 |
Letter by Stollberger and Finsterer regarding article, "intracranial hemorrhage in patients with atrial fibrillation during anticoagulation with Warfarin or Dabigatran: the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial".
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracranial Hemorrhages; Male; W | 2012 |
Removal of dabigatran by hemodialysis.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Overdose; Humans; I | 2013 |
Treatment of acute stroke in patients on dabigatran: a survey of US stroke specialists.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Health Care Surveys; H | 2013 |